John Martin Sowerby, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Proteins | 1 | 2017 | 1192 | 0.390 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 2210 | 0.300 |
Why?
|
| Neutrophils | 2 | 2017 | 3782 | 0.250 |
Why?
|
| Chemokine CXCL13 | 1 | 2024 | 62 | 0.230 |
Why?
|
| Immune System | 2 | 2021 | 800 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2024 | 287 | 0.220 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2022 | 38 | 0.210 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2024 | 223 | 0.190 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2022 | 175 | 0.190 |
Why?
|
| Germinal Center | 2 | 2020 | 379 | 0.170 |
Why?
|
| Interferon Type I | 1 | 2024 | 568 | 0.170 |
Why?
|
| Phagocytes | 2 | 2022 | 292 | 0.170 |
Why?
|
| Haploinsufficiency | 1 | 2021 | 334 | 0.160 |
Why?
|
| B-Lymphocytes | 3 | 2022 | 4784 | 0.150 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2024 | 1144 | 0.150 |
Why?
|
| Gray Platelet Syndrome | 1 | 2017 | 7 | 0.150 |
Why?
|
| Respiratory Burst | 1 | 2017 | 110 | 0.140 |
Why?
|
| Plasma Cells | 1 | 2020 | 599 | 0.130 |
Why?
|
| Receptors, IgG | 1 | 2019 | 562 | 0.130 |
Why?
|
| Cytosol | 1 | 2017 | 886 | 0.110 |
Why?
|
| Mutation | 2 | 2022 | 30220 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 1 | 2020 | 1612 | 0.110 |
Why?
|
| Reactive Oxygen Species | 2 | 2022 | 2143 | 0.110 |
Why?
|
| Immunophenotyping | 1 | 2017 | 1866 | 0.100 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2024 | 2156 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2024 | 4410 | 0.090 |
Why?
|
| Immune Tolerance | 1 | 2019 | 2324 | 0.080 |
Why?
|
| Staphylococcus aureus | 1 | 2017 | 1429 | 0.080 |
Why?
|
| Cell Differentiation | 3 | 2024 | 11648 | 0.080 |
Why?
|
| Staphylococcal Infections | 1 | 2017 | 1396 | 0.080 |
Why?
|
| Mycobacterium ulcerans | 1 | 2007 | 9 | 0.070 |
Why?
|
| Blood Platelets | 1 | 2017 | 2465 | 0.070 |
Why?
|
| Mice, Knockout | 2 | 2020 | 14466 | 0.060 |
Why?
|
| Skin Ulcer | 1 | 2007 | 131 | 0.060 |
Why?
|
| Signal Transduction | 4 | 2022 | 23611 | 0.060 |
Why?
|
| Autoimmunity | 2 | 2022 | 1356 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2019 | 10438 | 0.050 |
Why?
|
| Mice | 5 | 2022 | 81863 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2020 | 12147 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2017 | 7866 | 0.040 |
Why?
|
| Colitis, Ulcerative | 1 | 2011 | 1918 | 0.040 |
Why?
|
| Phenotype | 1 | 2017 | 16721 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2011 | 2285 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2024 | 975 | 0.040 |
Why?
|
| Epigenomics | 1 | 2024 | 959 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2011 | 4652 | 0.040 |
Why?
|
| Cytochrome b Group | 1 | 2017 | 59 | 0.040 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2020 | 546 | 0.030 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2021 | 606 | 0.030 |
Why?
|
| Animals | 5 | 2022 | 168887 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 608 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2020 | 1392 | 0.030 |
Why?
|
| Pedigree | 1 | 2021 | 4537 | 0.030 |
Why?
|
| Neoplasms | 1 | 2022 | 22343 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2019 | 1851 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 3803 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2017 | 1527 | 0.020 |
Why?
|
| Interleukin-7 | 1 | 2011 | 146 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2017 | 1132 | 0.020 |
Why?
|
| Alleles | 1 | 2021 | 6894 | 0.020 |
Why?
|
| Humans | 9 | 2024 | 766432 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 5502 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2019 | 5890 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2024 | 9521 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 7475 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2017 | 4270 | 0.020 |
Why?
|
| Victoria | 1 | 2007 | 64 | 0.020 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2007 | 65 | 0.020 |
Why?
|
| Cytokines | 1 | 2021 | 7436 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 3702 | 0.020 |
Why?
|
| Models, Biological | 1 | 2021 | 9458 | 0.020 |
Why?
|
| Software | 1 | 2019 | 4464 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2017 | 3078 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2020 | 18979 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 10263 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2021 | 22245 | 0.010 |
Why?
|
| Male | 5 | 2024 | 363975 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2021 | 42576 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2011 | 2570 | 0.010 |
Why?
|
| Female | 5 | 2024 | 396354 | 0.010 |
Why?
|
| Macrophages | 1 | 2017 | 5782 | 0.010 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2007 | 641 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2007 | 2653 | 0.010 |
Why?
|
| Algorithms | 1 | 2019 | 14071 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 22337 | 0.010 |
Why?
|
| Child | 2 | 2021 | 80668 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 6306 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 8536 | 0.010 |
Why?
|
| Prognosis | 1 | 2011 | 29922 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 54826 | 0.000 |
Why?
|
| Middle Aged | 2 | 2011 | 223127 | 0.000 |
Why?
|
| Adult | 2 | 2011 | 223253 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2007 | 59538 | 0.000 |
Why?
|
| Adolescent | 1 | 2007 | 88898 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2007 | 81588 | 0.000 |
Why?
|
| Aged | 1 | 2007 | 171234 | 0.000 |
Why?
|